Caprolactam Chemicals Ltd. Exempt from SEBI RPT Disclosures Due to Small Capital

CHEMICALS
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Caprolactam Chemicals Ltd. Exempt from SEBI RPT Disclosures Due to Small Capital
Overview

Caprolactam Chemicals Ltd. has informed SEBI it is exempt from disclosing Related Party Transactions (RPTs). This is because its paid-up equity share capital and net worth remain below regulatory thresholds, simplifying compliance. However, future growth could trigger these requirements.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Caprolactam Chemicals Ltd. Exempt from RPT Disclosures on Small Scale

Caprolactam Chemicals Ltd.'s paid-up equity share capital stood at ₹4.60 crore as of March 31, 2025, with its net worth at ₹4.96 crore on the same date.

Regulatory Update

Caprolactam Chemicals Ltd. has informed the BSE that it is exempt from SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning the disclosure of Related Party Transactions (RPTs).

This exemption is due to the company's paid-up equity share capital of ₹4.60 crore and net worth of ₹4.96 crore as of March 31, 2025. Both figures are below SEBI's stipulated thresholds of ₹10 crore for paid-up capital and ₹25 crore for net worth.

As a result, the company avoids the need to submit RPT disclosures for the relevant period, greatly reducing its regulatory compliance burden.

Why This Matters

This exemption allows Caprolactam Chemicals to save time and resources, redirecting management focus toward core business operations instead of preparing extensive RPT disclosures.

Company Background

Caprolactam Chemicals Ltd. manufactures basic chemicals like Glycol Ethers and Ethyl Acetate, and also provides contract manufacturing services. The company was incorporated in 1988 and is based in Mahad, Maharashtra. It was previously a sick unit registered with BIFR in 2001 but recovered and was deregistered by 2018. For the financial year ending March 31, 2025, the company reported revenue of ₹6.75 crore.

What Changes Now

  • Regulatory compliance is now simplified for Caprolactam Chemicals Ltd.
  • The company does not need to prepare and submit detailed RPT disclosures for the current period.
  • Management can focus more on operational efficiency and business growth.

Risks to Watch

If Caprolactam Chemicals' paid-up capital or net worth increase and surpass SEBI's thresholds of ₹10 crore and ₹25 crore, respectively, in future financial periods, the company will become subject to mandatory Related Party Transaction disclosure requirements.

Peer Comparison

While direct peers are not readily comparable for this specific exemption, SEBI's rules on related party transactions (Regulation 23 of LODR) are generally applied to listed entities to ensure corporate governance. Companies with significantly higher capital and net worth typically face more stringent disclosure obligations.

Key Metrics for Disclosure Exemption

  • Paid-up Equity Share Capital: ₹4.60 crore (As of March 31, 2025, Standalone).
  • Net Worth: ₹4.96 crore (As of March 31, 2025, Standalone).

What to Track Next

  • Monitor future financial results and balance sheet disclosures for changes in paid-up capital and net worth.
  • Observe if the company's financial growth trajectory brings it closer to or above SEBI's disclosure thresholds.
  • Evaluate any strategic initiatives that might involve capital infusion or significant profit retention affecting net worth.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.